Other languages Magenta Therapeutics

Equities

MGTA

US55910K1088

Market Closed - Nasdaq Other stock markets 21:00:00 29/04/2024 BST			5-day change	1st Jan Change
21.9 ^USD	+1.86%		-7.53%	+95.65%

2023	Magenta Therapeutics, Inc.(NasdaqCM:MGTA) dropped from NASDAQ Composite Index	CI
2023	Dianthus Therapeutics, Inc. completed the acquisition of Magenta Therapeutics, Inc. from a group of shareholders in a reverse merger transaction.	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Dianthus Therapeutics, Inc. completed the acquisition of Magenta Therapeutics, Inc. from a group of shareholders in a reverse merger transaction.	10/09/23
Magenta Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	03/08/23
Magenta Therapeutics, Inc. Announces Resignation of Lisa Olson as Head of Research and Chief Scientific Officer	19/05/23
Magenta Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	15/05/23
Magenta Therapeutics, Inc. Enters into Sublease Termination and Release Agreement with Novartis Institutes for Biomedical Research, Inc	06/04/23
Magenta Therapeutics, Inc. Announces Management Changes	07/02/23
Magenta Therapeutics, Inc. Announces the Resignation of Jason Gardner, Chief Executive Officer	07/02/23
Rapid January Jobs Growth and Weak Tech Earnings Weigh on US Equity Futures	03/02/23
Top Premarket Gainers	03/02/23
Top Premarket Decliners	26/01/23
Magenta Therapeutics Voluntarily Pauses the MGTA-117 Phase 1/2 Dose-Escalation Clinical Trial to Investigate Drug Safety	25/01/23
Top Midday Decliners	20/12/22
Magenta Therapeutics Says it Stopped Group Four Dosing in MGTA-117 Trial; Shares Plunge	20/12/22
Magenta Therapeutics Provides Update for MGTA-117 Phase 1/2 Dose Escalation Clinical Trial	20/12/22
Better-Than-Expected Inflation Data Seen Boosting US Equities	13/12/22
Top Premarket Gainers	13/12/22
Magenta Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	03/11/22
Magenta Therapeutics, Inc. to Present Data At the 2022 American Society of Hematology Annual Meeting	03/11/22
Magenta Therapeutics Announces Appointment of Michael Vasconcelles to its Board of Directors, R&D Committee and Nominating and Corporate Governance Committee	17/08/22
Magenta Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	04/08/22

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Magenta Therapeutics

Equities

MGTA

US55910K1088

Other languages

Filters